Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Electrofect AS, Boehringer Ingelheim GmbH International deal

By WIR Staff | Feb 28, 2000 | 8:00 AM GMT

Boehringer received a

Read the full 36 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE